# Eli Lilly and Company â€” Equity Valuation Report

**Date:** February 17, 2026  
**Ticker:** LLY  
**Sector:** Healthcare â€” Drug Manufacturers - General  
**Currency:** USD  

---

## Executive Summary

| Metric | Value |
|--------|-------|
| **Intrinsic Value / Share** | **â‚¬992** |
| Current Market Price | ~â‚¬1,006 |
| Upside / Downside | -1.4% |
| Verdict | ðŸŸ¡ FAIRLY VALUED |
| Enterprise Value | â‚¬924B |
| Equity Value | â‚¬890B |
| WACC | 6.78% |
| Terminal Growth | 2.5% |
| TV as % of EV | 71% |

## 1. Business Overview

_Eli Lilly and Company is a leading company in the Healthcare sector._

**Latest fiscal year (FY2025):**
- Revenue: â‚¬65.2B
- Net income: â‚¬20.6B
- Gross margin: 83.0%
- Operating margin: nan%
- Market cap: ~$981B USD

## 2. Historical Financial Performance

### Revenue & Profitability (10-Year History)

| FY | Revenue (â‚¬B) | Growth | Gross Margin | Op. Margin | Net Margin |
|---:|-------------:|-------:|-------------:|-----------:|-----------:|
| 2016 | 21.2 | â€” | 73.1% | 18.0% | 12.9% |
| 2017 | 22.9 | +7.8% | 73.1% | 21.2% | -0.9% |
| 2018 | 24.6 | +7.4% | 73.8% | 25.2% | 13.2% |
| 2019 | 22.3 | -9.1% | 78.8% | 25.9% | 37.3% |
| 2020 | 24.5 | +9.9% | 77.7% | 27.9% | 25.2% |
| 2021 | 28.3 | +15.4% | 74.2% | 26.7% | 19.7% |
| 2022 | 28.5 | +0.8% | 76.8% | 29.0% | 21.9% |
| 2023 | 34.1 | +19.6% | 79.2% | nan% | 15.4% |
| 2024 | 45.0 | +32.0% | 81.3% | nan% | 23.5% |
| 2025 | 65.2 | +44.7% | 83.0% | nan% | 31.7% |

**Compound Annual Growth Rates:**
- 3-year CAGR: **31.7%**
- 5-year CAGR: **21.6%**
- 9-year CAGR: **13.3%**

## 3. Return on Invested Capital (ROIC)

ROIC is the central metric for assessing whether ASML creates value â€” it measures how much operating profit the company generates per euro of capital invested.

| FY | NOPAT (â‚¬B) | Invested Capital (â‚¬B) | ROIC | ROE |
|---:|-----------:|----------------------:|-----:|----:|
| 2016 | 2.9 | 32.9 | nan% | nan% |
| 2017 | 1.9 | 37.0 | 5.7% | -1.5% |
| 2018 | 3.2 | 34.5 | 8.7% | 27.9% |
| 2019 | 7.6 | 35.5 | 22.0% | 84.6% |
| 2020 | 6.1 | 41.4 | 17.3% | 237.6% |
| 2021 | 5.2 | 43.3 | 12.6% | 98.9% |
| 2022 | 5.8 | 45.5 | 13.4% | 69.5% |
| 2023 | 5.6 | 58.6 | 12.2% | 49.2% |
| 2024 | 10.8 | 72.2 | 18.4% | 98.3% |
| 2025 | 21.9 | 99.8 | 30.3% | 145.4% |

**3-year average ROIC: 20.3%** â€” well above the cost of capital (WACC â‰ˆ 8.5%), confirming ASML's exceptional value creation.

## 4. Working Capital & Cash Conversion

| FY | NWC (â‚¬B) | Î”NWC (â‚¬B) | DSO | DIO | DPO | CCC (days) |
|---:|---------:|-----------:|----:|----:|----:|-----------:|
| 2021 | 8.9 | +0.6 | 86 | 194 | 83 | 197 |
| 2022 | 9.3 | +0.4 | 88 | 237 | 106 | 219 |
| 2023 | 12.3 | +3.0 | 97 | 298 | 134 | 261 |
| 2024 | 15.4 | +3.1 | 89 | 329 | 140 | 278 |
| 2025 | 26.1 | +10.8 | 99 | 454 | 178 | 376 |

**Key observation:** ASML's cash conversion cycle is **376 days**, reflecting the 6â€“12 month build times for EUV systems. Days inventory outstanding (454 days) is particularly high, which is structural for capital equipment manufacturers.

## 5. Cost of Capital (WACC)

### CAPM Inputs

| Parameter | Value | Source |
|-----------|------:|--------|
| Risk-free rate (Rf) | 4.5% | 10y German Bund |
| Equity beta (Î²) | 0.50 | Analyst estimate (< Yahoo's 1.46) |
| Equity risk premium | 5.0% | Damodaran mature market |
| Country risk premium | 0.0% | Netherlands (AAA) |

### Capital Structure (Market Values)

| Component | Value | Weight |
|-----------|------:|-------:|
| Equity (market cap) | â‚¬903B | 95.7% |
| Debt (book value) | â‚¬40.9B | 4.3% |

### Result

| Metric | Value |
|--------|------:|
| Cost of equity (Râ‚‘) | 7.00% |
| Cost of debt (after-tax) | 1.95% |
| **WACC** | **6.78%** |

*Note: ASML uses minimal financial leverage (D/V < 1%), so WACC is dominated by the cost of equity. The beta of 1.10 is a conservative estimate â€” Yahoo Finance reports 1.46, which would raise WACC to ~10%.*

## 6. DCF Valuation

### Key Assumptions

| Assumption | Value | Rationale |
|------------|------:|-----------|
| Near-term growth (Yr 1â€“5) | [25.0%, 22.0%, 18.0%, 12.0%, 8.0%] | Company guidance + consensus |
| Long-term growth (Yr 6â€“10) | 4% fade | Secular semi growth |
| Terminal growth (gâˆž) | 2.5% | ~ EUR nominal GDP |
| Operating margin target | 40% | ASML 2030 guidance (GM 56â€“60%) |
| Margin fade period | 5 years | Linear from 40.0% â†’ 40% |
| Capex / Revenue | 10% | Elevated â€” capacity buildout |
| Î”NWC / Î”Revenue | 15% | Marginal working capital rate |
| Tax rate | 15% | Blended effective rate |

### FCFF Projections

| Year | FY | Growth | Revenue (â‚¬B) | Op. Margin | NOPAT (â‚¬B) | FCFF (â‚¬B) |
|-----:|---:|-------:|-------------:|-----------:|-----------:|----------:|
| 1 | 2026 | 25.0% | 81.5 | 40.0% | 27.7 | 21.2 |
| 2 | 2027 | 22.0% | 99.4 | 40.0% | 33.8 | 26.1 |
| 3 | 2028 | 18.0% | 117.3 | 40.0% | 39.9 | 31.3 |
| 4 | 2029 | 12.0% | 131.4 | 40.0% | 44.7 | 36.0 |
| 5 | 2030 | 8.0% | 141.9 | 40.0% | 48.2 | 39.6 |
| 6 | 2031 | 7.2% | 152.1 | 40.0% | 51.7 | 42.6 |
| 7 | 2032 | 6.4% | 161.8 | 40.0% | 55.0 | 45.5 |
| 8 | 2033 | 5.6% | 170.9 | 40.0% | 58.1 | 48.2 |
| 9 | 2034 | 4.8% | 179.1 | 40.0% | 60.9 | 50.7 |
| 10 | 2035 | 4.0% | 186.2 | 40.0% | 63.3 | 52.9 |

### Valuation Waterfall

| Component | Value (â‚¬B) | % of EV |
|-----------|----------:|--------:|
| PV of explicit FCFF (Yr 1â€“10) | 266.2 | 29% |
| PV of terminal value | 657.6 | 71% |
| **Enterprise Value** | **923.8** | **100%** |
| âˆ’ Net Debt | 33.6 | â€” |
| **Equity Value** | **890.2** | â€” |
| Ã· Shares outstanding | 897M | â€” |
| **Intrinsic Value / Share** | **â‚¬992** | â€” |

## 7. Sensitivity Analysis

### Value Driver Ranking (Tornado)

Which parameters have the biggest impact on intrinsic value?

| Rank | Parameter | Range | Low | High | Swing |
|-----:|-----------|------:|----:|-----:|------:|
| 1 | growth_rate | 3% â†’ 18% | â‚¬480 | â‚¬1,574 | â‚¬1,094 |
| 2 | wacc_rate | 7% â†’ 11% | â‚¬494 | â‚¬239 | â‚¬254 |
| 3 | operating_margin | 28% â†’ 42% | â‚¬321 | â‚¬555 | â‚¬234 |
| 4 | terminal_growth | 2% â†’ 4% | â‚¬446 | â‚¬642 | â‚¬195 |
| 5 | capex_to_revenue | 4% â†’ 10% | â‚¬639 | â‚¬521 | â‚¬118 |
| 6 | tax_rate | 10% â†’ 20% | â‚¬561 | â‚¬482 | â‚¬79 |
| 7 | nwc_to_revenue | 10% â†’ 20% | â‚¬525 | â‚¬518 | â‚¬8 |

**Key insight:** Revenue growth is by far the most impactful parameter, with a swing of **â‚¬1,094** between bear and bull cases. WACC ranks second, followed by operating margins.

### WACC Ã— Terminal Growth (Value / Share)

| WACC \ gâˆž | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---:|---:|---:|---:|---:|---:|
| 6.8% | â‚¬445 | â‚¬478 | â‚¬519 | â‚¬571 | â‚¬638 |
| 7.0% | â‚¬426 | â‚¬457 | â‚¬494 | â‚¬540 | â‚¬599 |
| 7.5% | â‚¬386 | â‚¬410 | â‚¬439 | â‚¬475 | â‚¬519 |
| 8.0% | â‚¬352 | â‚¬372 | â‚¬395 | â‚¬423 | â‚¬457 |
| 8.5% | â‚¬323 | â‚¬339 | â‚¬358 | â‚¬380 | â‚¬407 |
| 9.5% | â‚¬276 | â‚¬287 | â‚¬300 | â‚¬315 | â‚¬332 |
| 10.0% | â‚¬257 | â‚¬266 | â‚¬277 | â‚¬290 | â‚¬304 |
| 10.5% | â‚¬240 | â‚¬248 | â‚¬257 | â‚¬267 | â‚¬279 |
| 11.0% | â‚¬224 | â‚¬231 | â‚¬239 | â‚¬248 | â‚¬258 |

### Revenue Growth Ã— WACC (Value / Share)

| Growth \ WACC | 6.8% | 7.0% | 7.5% | 8.0% | 8.5% | 9.5% | 10.0% | 10.5% | 11.0% |
|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| 4% | â‚¬519 | â‚¬494 | â‚¬439 | â‚¬395 | â‚¬358 | â‚¬300 | â‚¬277 | â‚¬257 | â‚¬239 |
| 6% | â‚¬611 | â‚¬581 | â‚¬516 | â‚¬463 | â‚¬420 | â‚¬351 | â‚¬323 | â‚¬299 | â‚¬278 |
| 8% | â‚¬718 | â‚¬682 | â‚¬605 | â‚¬543 | â‚¬491 | â‚¬409 | â‚¬376 | â‚¬348 | â‚¬323 |
| 10% | â‚¬842 | â‚¬800 | â‚¬709 | â‚¬634 | â‚¬573 | â‚¬476 | â‚¬438 | â‚¬404 | â‚¬375 |
| 12% | â‚¬986 | â‚¬936 | â‚¬828 | â‚¬740 | â‚¬667 | â‚¬553 | â‚¬508 | â‚¬469 | â‚¬434 |
| 14% | â‚¬1,153 | â‚¬1,094 | â‚¬966 | â‚¬863 | â‚¬777 | â‚¬643 | â‚¬589 | â‚¬543 | â‚¬502 |
| 16% | â‚¬1,345 | â‚¬1,275 | â‚¬1,125 | â‚¬1,003 | â‚¬902 | â‚¬745 | â‚¬682 | â‚¬628 | â‚¬580 |
| 18% | â‚¬1,566 | â‚¬1,484 | â‚¬1,308 | â‚¬1,165 | â‚¬1,047 | â‚¬862 | â‚¬789 | â‚¬725 | â‚¬670 |

## 8. Reverse DCF â€” What the Market Implies

Instead of asking *"what is ASML worth?"*, we ask *"what must the market be assuming to justify the current price?"* Each parameter is solved independently while holding all others at base-case values.

| Parameter | Implied Value | Our Assumption | Plausible? |
|-----------|-------------:|---------------:|:----------:|
| Revenue growth (p.a.) | 12.2% | 4% | â— |
| Operating margin | 69.0% | 40% | âš  |
| WACC | 4.81% | 6.78% | âš  |
| Terminal growth | 4.86% | 2.5% | âš  |

**Interpretation:** To justify ~â‚¬1,006/share through growth alone, ASML would need to compound revenue at **12.2%** annually for 10 years, reaching **â‚¬206B** by FY2035. This would make ASML larger than the entire WFE market today. No single assumption justifies the price â€” the market is pricing in multiple favourable outcomes simultaneously.

## 9. Key Risks & Catalysts

### Upside Catalysts

- **High-NA EUV ramp:** Successful volume deployment of next-gen systems (â‚¬350M+ ASP vs ~â‚¬200M for standard EUV) could accelerate revenue and margins
- **AI capex supercycle:** Sustained hyperscaler investment in AI chips drives leading-edge node demand beyond current consensus
- **Installed base growth:** Service & upgrade revenue (~30% of total) grows predictably as the EUV fleet expands
- **Geopolitical reshoring:** CHIPS Act and EU subsidies drive incremental fab construction, expanding the addressable market

### Downside Risks

- **Cyclical downturn:** Semiconductor capex is highly cyclical; a 30â€“40% peak-to-trough revenue decline is historically normal
- **China export restrictions:** Further tightening could remove ~15% of addressable market (DUV sales to China)
- **Customer concentration:** Top 3 customers (TSMC, Samsung, Intel) represent ~80%+ of system revenue
- **Execution risk on High-NA:** Delays or yield issues could push out the growth inflection point
- **Valuation compression:** Multiple contraction if growth expectations are not met or interest rates remain elevated

## 10. Methodology & Data Sources

### Approach

This report uses a **two-stage Discounted Cash Flow (DCF)** model:

1. **Explicit period (10 years):** Revenue is projected using near-term company guidance and consensus estimates, fading to long-term secular growth. Operating margins fade linearly from current levels to long-run targets over 5 years.
2. **Terminal value:** Beyond year 10, FCFF grows at a perpetual rate (gâˆž = 2.5%) and is capitalised using the Gordon Growth formula.

The model is supplemented with:
- **Sensitivity analysis** (two-way tables for WACC Ã— growth, growth Ã— margins)
- **Tornado charts** ranking parameter importance
- **Reverse DCF** solving for market-implied expectations

### Data Sources

| Source | Data | Update Frequency |
|--------|------|-----------------|
| SEC EDGAR (XBRL API) | 10 years of annual financials | Annual (20-F filings) |
| Yahoo Finance | Market cap, beta, price history | Real-time |
| ASML Investor Day (Nov 2024) | 2030 revenue & margin targets | Ad hoc |
| Analyst consensus | Near-term revenue estimates | Quarterly |
| Damodaran | Equity risk premium, country risk | Annual |

### Limitations

- Financial data is based on reported XBRL tags, which may differ slightly from manually adjusted figures
- The model uses a constant WACC, which may overstate the discount for a company with minimal leverage
- Near-term growth estimates reflect consensus as of the report date and may change with updated guidance
- Market cap uses the NYSE ADR price converted to EUR at a fixed rate

---

*This report was generated programmatically by the ASML Valuation Framework. All assumptions are documented in `config/assumptions.yaml` and can be modified to produce alternative scenarios.*
